Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)

v3.23.3
Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) - USD ($)
$ in Thousands
 1 Months Ended 9 Months Ended
Jul. 31, 2022
Sep. 30, 2023
Agreements    
Short-term royalty receivable, Balance at beginning of period   $ 2,366
Short-term royalty receivable, Balance at end of period   0
Long-term royalty receivable, Balance at beginning of period   63,683
Impairment of royalty and commercial payment rights, Long-Term   (1,575)
Long-term royalty receivable, Balance at end of period   74,696
Affitech    
Agreements    
Receipt of royalty and commercial payments, Short-Term   (7,284)
Recognition of contingent consideration, Long-Term   3,000
Reclassification to short-term royalty and commercial payment receivables, Short-Term   4,918
Reclassification to short-term royalty and commercial payment receivables, Long-Term   (4,918)
Aptevo    
Agreements    
Acquisition of royalty and commercial payment rights, Long-Term   9,650
Receipt of royalty and commercial payments, Long-Term   (1,144)
LadRx    
Agreements    
Acquisition of royalty and commercial payment rights, Long-Term   6,000
Bioasis    
Agreements    
Impairment of royalty and commercial payment rights, Long-Term   $ (1,575)
Royalty Purchase Agreement | Kuros    
Agreements    
Receipt of royalty and commercial payments, Long-Term $ (2,500)